2022
DOI: 10.1001/jamainternmed.2022.0605
|View full text |Cite
|
Sign up to set email alerts
|

Efficacy and Safety of Daprodustat for Treatment of Anemia of Chronic Kidney Disease in Incident Dialysis Patients

Abstract: Key Points Question Is daprodustat, a hypoxia-inducible factor prolyl hydroxylase inhibitor, an effective oral alternative to darbepoetin alfa in the treatment of anemia of chronic kidney disease (CKD) in incident dialysis (ID) patients? Findings In this randomized clinical trial of 312 ID patients, daprodustat was noninferior to darbepoetin alfa in treating anemia of CKD; the difference in mean hemoglobin concentration between study arms during the evaluat… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

3
46
0

Year Published

2022
2022
2024
2024

Publication Types

Select...
8

Relationship

1
7

Authors

Journals

citations
Cited by 32 publications
(49 citation statements)
references
References 29 publications
3
46
0
Order By: Relevance
“…However, an increasing number of patients also present clinically with EPO hyporesponse, which may be related to factors such as iron metabolism disorder and EPO receptor dysfunction. Recently, with the application of hypoxia inducible factor prolyl hydroxylase inhibitor (HIF-PHI) in the clinic, the standard rate of treatment of renal anemia in ESRD dialysis patients has been further improved [ 23 , 24 ]. However, renal anemia is a multifactorial disease, and the diversity of its etiologies has contributed to its need for multitarget therapies.…”
Section: Discussionmentioning
confidence: 99%
“…However, an increasing number of patients also present clinically with EPO hyporesponse, which may be related to factors such as iron metabolism disorder and EPO receptor dysfunction. Recently, with the application of hypoxia inducible factor prolyl hydroxylase inhibitor (HIF-PHI) in the clinic, the standard rate of treatment of renal anemia in ESRD dialysis patients has been further improved [ 23 , 24 ]. However, renal anemia is a multifactorial disease, and the diversity of its etiologies has contributed to its need for multitarget therapies.…”
Section: Discussionmentioning
confidence: 99%
“…In this post hoc exploratory analysis, cardiovascular safety results from eligible patients with anemia of CKD enrolled in four phase 3,randomized,openlabel studies (NDD [DOLOMITES] or ID-DD [SIERRAS, HIMALAYAS, ROCKIES]) were pooled and compared between roxadustat and an ESA. Time to major adverse cardiovascular event (MACE), MACE+ (MACE plus congestive heart failure or unstable angina requiring hospitalization), and all-cause mortality (ACM) was evaluated in subgroups established from baseline characteristics.…”
Section: Methods or Case Descriptionmentioning
confidence: 99%
“…were considered having a systemic disease. The remaining 393 SF (321 calcium, 63 uric acid, 9 infection) were screened for full MS/features thereof (definition IDF [2]), LDL-cholesterol (LDL-C) >3.0 mmol/l ( risk for coronary death [3]), urine volume <1.2 L/d likely caused by reduced thirst sensitivity/AVP dysregulation [4], and low bone mass.…”
Section: Methods or Case Descriptionmentioning
confidence: 99%
See 1 more Smart Citation
“…In the daprodustat program, there were no differences in IV iron utilization between the HIF-PH inhibitor and comparator ESA groups apart from a subgroup of hyporesponders in the DD study who required slightly less IV iron [8 ▪▪ ,9 ▪▪ ]. In the Japanese phase 3 program, 32% of patients receiving daprodustat required intravenous iron during the treatment period compared to 43% with darbepoetin [21], and in a study of incident dialysis patients, daprodustat was not superior compared to darbepoetin alfa in reducing monthly IV iron use (adjusted mean treatment difference, 19.4 mg [95% CI: –11.0 to 49.9 mg]), with a reduction in mean monthly IV iron use from baseline to week 52 in both treatment groups [22]. No data are reported for iron utilization in the vadadustat program [6 ▪▪ ,7 ▪▪ ].…”
Section: Effect On Iron Availabilitymentioning
confidence: 98%